randomly assigned 55 patients with biopsy-confirmed NASH and either impaired glucose tolerance or type 2 diabetes to receive a hypocaloric diet plus either pioglitazone (30 mg daily for 2 months ...

Participants were randomly allocated to 16 weeks of either active (pioglitazone 30 mg daily) or placebo treatment. One woman in each group withdrew (one pregnancy and one adverse reaction to ...

Nonalcoholic steatohepatitis (NASH) is an increasingly common cause of chronic liver disease worldwide. Currently, no specific pharmacologic therapy has been shown to treat NASH effectively.

US-based Mylan Pharmaceuticals gained FDA approval for 15 milligram, 30 mg and 45 mg pioglitazone tablets. Along with diet and exercise, pioglitazone is used to improve blood glucose control in ...